ECG-PH clearance adds pulmonary hypertension to Tempus’ FDA-cleared AI products for atrial fibrillation and low ejection fraction
Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model.
Tempus' multimodal foundation model offers diagnostic-grade precision for cancer detection and unlocks broader applications predicting biomarker status and patient prognosis
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026. “Q2 was another...
Tempus AI is set to report its Q2 results today. Investors will be watching.
Barchart Research What to Expect from TEM Earnings TEM Generated July 29, 2026 Current Price $41.55 EPS Estimate $$-0.41 Consensus Rating Moderate Buy Average Move 6.67% Tempus AI Has Set Itself Up for...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Personalis ,...
Tempus AI ($TEM) has agreed to acquire Personalis ($PSNL) in an all-stock transaction valued at approximately $1.5 billion in enterprise value, expanding its capabilities in minimal residual disease (MRD)...